logo
Plus   Neg
Share
Email

Lexicon Phase 2 Trial Of Anti-Tumor Drug Meets Primary Endpoint, Begins Phase 3

Lexicon Pharmaceuticals, Inc. (LXRX), a biopharmaceutical company announced new data from its recently completed Phase 2 study of its investigational drug telotristat etiprate for carcinoid tumors. Through the trial, the drug achieved its primary endpoint that is the reduction of bowel movements from baseline at week 12 in 46.4 percent of the patients involved in the study and suffering from metastatic carcinoid syndrome. In addition, the company said it would present the data from the trial at the North American Neuroendocrine Tumor Society on October 13 in California.

Further, the company added Telotristat etiprate, administered orally was well tolerated by the patients with only three of the patients reporting serious adverse events, none of which was related to study drug.

In a statement, the company said it is also initiating a 12-week registrational Phase 3 trail that is designed to test the drug's safety, efficacy after its positive outlook in the Phase 2 trials, said Lexicon in a statement.

For comments and feedback contact: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
MillerCoors LLC has filed a lawsuit against Anheuser-Busch Companies LLC, part of Anheuser-Busch InBev, alleging that Anheuser-Busch's ad campaigns associating MillerCoors' products, Miller Lite and Coor Light, with corn syrup is "false and misleading." During the Super Bowl, ABInBev ran an advertising campaign that mocked Miller Lite and Coors Light use corn syrup in brewing. Shares of Biogen Inc. are falling almost 28 percent in Thursday's trading after the company and Japanese drugmaker Eisai Co. said they will discontinue two late-stage trials for their experimental Alzheimer's drug, Aducanumab. The two Phase 3 trials, ENGAGE and EMERGE, are multi-center, randomized, double-blind, placebo-controlled, parallel-group studies designed to evaluate Aducanumab. The European Union on Wednesday ordered Alphabet Inc.'s Google to pay an antitrust fine of 1.49 billion euros for abusing its dominant position in the online search advertising intermediation market by preventing competition. This is the third antitrust fine by the EU against Google and it represents 1.29 percent of the tech giant's turnover in 2018.
Follow RTT